BrainXell focuses on neural cells for therapeutic development. It was founded in 2015 with a startup grant to Professor Su-Chun Zhang by the Discovery to Product (D2P) program of the University of Wisconsin Madison. It is based on the proprietary technology in directed differentiation of human stem cells (including induced pluripotent stem cells) to highly enriched subclasses of neural progenitors, expansion of committed neural progenitors to large quantities, and rapid maturation to functional neurons and glia. BrainXell is developing drug discovery / toxicology testing platforms using patient-derived or genetically modified stem cells for as well as provide services to pharmaceutical and biotechnology industry. BrainXell also aims to develop stem cell therapy for neurological injuries and diseases through collaboration with pharmaceutical and healthcare industry. BrainXell’s goal is to make our brain healthy and well.
|Neuron Type||Neuronal Purity||Time to Use||Catalog Number|
|Spinal Cord Motor Neurons||>90%||5 - 10 days||BX-0100|
|>80%||10 - 18 days||BX-0200|
|Glutamatergic Neurons||>90%||7 - 14 days||BX-0300|
|GABAergic Neurons||>90%||7 - 14 days||BX-0400|
|Mixed Cortical Neurons||>90%||7 - 14 days||BX-0500|
|Medium Spiny Striatal GABAergic Neurons||>70%||7 - 14 days||BX-0700|
|Parvalbumin-Enriched Cortical GABAergic Neurons||>10%||7 - 14 days||BX-0450|
|Layer V Cortical Glutamatergic Neurons||>80%||7 - 14 days||BX-0350|
Neurons from Specific iPSCs
Any of the neuron types listed under Products can be produced from customer-supplied induced pluripotent cells (iPSCs) or embryonic stem cells (ESCs). The iPSCs can be derived from either healthy controls, individuals with a sporadic disease, or individuals with a disease mutation. From the receipt of cells, delivery time is typically two to three months with quantities of up to half a billion neurons.
Large batch sizes of up to two billion neurons are available for all neuron types.
In-House Assays for Motor Neuron Diseases
A range of custom assays can be performed on in-house models of two motor neuron diseases, spinal muscular atrophy and amyotrophic lateral sclerosis. Please inquire for assay and model specifics.
Discovery & Neurotoxicity
Functional Activity – Calcium Influx
Functional Activity – Action Potentials
Functional Activity – Multi-Electrode Array (MEA)
Neurological traumas, such as spinal cord injury, and neurodegenerative disorders, such as Parkinson’s disease, often lack effective treatment. Stem cell therapy presents a promising alternative. BrainXell has pioneered in producing highly enriched, functionally specialized neural cells from human stem cells, including cortical glutamate neurons, cortical GABA neurons, forebrain cholinergic neurons, striatal medium spinal GABA neurons, midbrain dopamine neurons, hindbrain serotonin neurons, spinal motor neurons, astrocytes, and oligodendrocytes. Importantly, these cells have been tested for their therapeutic potential in animal models of neurological diseases, including Huntington’s disease, Parkinson’s disease, epilepsy, spinal cord injury, and multiple sclerosis. We are currently examining the efficacy and safety of these cells in pre-clinical models of diseases. Meanwhile, we are building working cell banks in the GMP facility.
Utilizing proprietary technology developed by Professor Su-Chun Zhang at the University of Wisconsin-Madison, we direct human stem cells, including iPSCs (licensed from iPS Japan) to subtype-specific neuronal progenitors, which are expanded to large quantities, followed by rapid maturation. This unique combination of technology enables large-scale production of highly enriched, functionally specialized neural cells with consistent quality for drug discovery and cell therapy.